Approval paves the way for expanded use across 32 European countries.
Biobot Surgical announced receiving CE mark approval for its Mona Lisa 2.0 surgical robotic platform, designed for prostate disease management. This milestone adds to its regulatory clearances in the U.S., Australia, and Singapore, expanding its reach across Europe.
Mona Lisa 2.0: Transforming Prostate Care
- Precision Targeting:
- Real-time adjustments for needle trajectory deviations caused by tissue heterogeneity or needle tip design.
- Visual overlays of lesion margins and simulated ablation zones for safer, more accurate treatments.
- Enhanced Efficiency:
- Multi-needle insertion reduces manual effort, optimizing workflow in complex procedures.
- Key Features:
- Supports prostate biopsies and ablations with real-time modeling for dynamic scenarios.
- Designed for future applications, including benign prostatic hyperplasia (BPH) interventions.
Global Impact on Urology
Albert Lee, CEO of Biobot Surgical, emphasized:
“The CE Certification of Mona Lisa 2.0 is a significant milestone. Its unmatched precision and adaptability are set to redefine prostate care across Europe, delivering superior patient outcomes.”
With advanced diagnostic and therapeutic capabilities, the Mona Lisa platform offers urologists a new level of confidence and efficiency in prostate care.
Follow MEDWIRE.AI for the latest on surgical robotics and global medtech advancements!
